Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access (EA) Trial of RT-001 to Treat Patients with Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

An Expanded Access (EA) Trial of RT-001 to Treat Patients with Amyotrophic Lateral Sclerosis (ALS)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Sep 2018

At a glance

  • Drugs RT 001 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 23 Sep 2018 New trial record
    • 17 Sep 2018 According to a Retrotope media release, the first amyotrophic lateral sclerosis patient has been dosed with RT001.
    • 17 Sep 2018 According to a Retrotope media release, the company has supplied its drug RT001 for the initiation of this expanded access (EA) trial to treat patients with amyotrophic lateral sclerosis (ALS).This EA program in ALS was requested by renowned investigators at major medical centers, is expected to enroll a few patients at each site and is intended to provide information to guide the design of future randomized placebo-controlled trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top